Cargando…

Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report

BACKGROUND: Biologics dramatically improve symptoms of severe asthma; however, various exacerbating factors may induce flare-up. Pneumocystis spp. have not been reported as a cause of asthma exacerbation during biologic use, although patients with severe asthma have high levels of antibodies against...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Kazuya, Sumi, Toshiyuki, Nagahisa, Yuta, Matsuura, Keigo, Sekikawa, Motoki, Watanabe, Hiroki, Yamada, Yuichi, Chiba, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035245/
https://www.ncbi.nlm.nih.gov/pubmed/35461263
http://dx.doi.org/10.1186/s13223-022-00678-y
_version_ 1784693255200309248
author Takeda, Kazuya
Sumi, Toshiyuki
Nagahisa, Yuta
Matsuura, Keigo
Sekikawa, Motoki
Watanabe, Hiroki
Yamada, Yuichi
Chiba, Hirofumi
author_facet Takeda, Kazuya
Sumi, Toshiyuki
Nagahisa, Yuta
Matsuura, Keigo
Sekikawa, Motoki
Watanabe, Hiroki
Yamada, Yuichi
Chiba, Hirofumi
author_sort Takeda, Kazuya
collection PubMed
description BACKGROUND: Biologics dramatically improve symptoms of severe asthma; however, various exacerbating factors may induce flare-up. Pneumocystis spp. have not been reported as a cause of asthma exacerbation during biologic use, although patients with severe asthma have high levels of antibodies against Pneumocystis spp. CASE PRESENTATION: An 87-year-old female with severe asthma that was well-controlled with mepolizumab, who developed a steroid-resistant refractory flare-up. Chest computed tomography showed bilateral ground glass opacities, and results of polymerase chain reaction tests on induced sputum were positive for Pneumocystis DNA. Therefore, a diagnosis of Pneumocystis pneumonia was made. The clinical symptoms improved after treatment with sulfamethoxazole–trimethoprim. CONCLUSION: Clinicians should be aware of Pneumocystis pneumonia as a cause of refractory exacerbation of bronchial asthma during use of interleukin-5 inhibitors.
format Online
Article
Text
id pubmed-9035245
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90352452022-04-25 Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report Takeda, Kazuya Sumi, Toshiyuki Nagahisa, Yuta Matsuura, Keigo Sekikawa, Motoki Watanabe, Hiroki Yamada, Yuichi Chiba, Hirofumi Allergy Asthma Clin Immunol Case Report BACKGROUND: Biologics dramatically improve symptoms of severe asthma; however, various exacerbating factors may induce flare-up. Pneumocystis spp. have not been reported as a cause of asthma exacerbation during biologic use, although patients with severe asthma have high levels of antibodies against Pneumocystis spp. CASE PRESENTATION: An 87-year-old female with severe asthma that was well-controlled with mepolizumab, who developed a steroid-resistant refractory flare-up. Chest computed tomography showed bilateral ground glass opacities, and results of polymerase chain reaction tests on induced sputum were positive for Pneumocystis DNA. Therefore, a diagnosis of Pneumocystis pneumonia was made. The clinical symptoms improved after treatment with sulfamethoxazole–trimethoprim. CONCLUSION: Clinicians should be aware of Pneumocystis pneumonia as a cause of refractory exacerbation of bronchial asthma during use of interleukin-5 inhibitors. BioMed Central 2022-04-23 /pmc/articles/PMC9035245/ /pubmed/35461263 http://dx.doi.org/10.1186/s13223-022-00678-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Takeda, Kazuya
Sumi, Toshiyuki
Nagahisa, Yuta
Matsuura, Keigo
Sekikawa, Motoki
Watanabe, Hiroki
Yamada, Yuichi
Chiba, Hirofumi
Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
title Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
title_full Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
title_fullStr Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
title_full_unstemmed Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
title_short Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
title_sort refractory flare-up of severe bronchial asthma controlled with mepolizumab due to pneumocystis pneumonia: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035245/
https://www.ncbi.nlm.nih.gov/pubmed/35461263
http://dx.doi.org/10.1186/s13223-022-00678-y
work_keys_str_mv AT takedakazuya refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport
AT sumitoshiyuki refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport
AT nagahisayuta refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport
AT matsuurakeigo refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport
AT sekikawamotoki refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport
AT watanabehiroki refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport
AT yamadayuichi refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport
AT chibahirofumi refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport